Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179
In development [GID-TA10450] Expected publication date: TBC
Search results
624 results
-
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: TBC
-
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]
In development [GID-TA10430] Expected publication date: TBC
-
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065
In development [GID-TA10385] Expected publication date: TBC
-
Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]
In development [GID-TA10572] Expected publication date: TBC
-
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Proposed [GID-TA10598] Expected publication date: TBC
-
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]
In development [GID-TA10342] Expected publication date: TBC
-
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
In development [GID-TA10495] Expected publication date: 18 August 2021
-
Tebentafusp for treating metastatic HLA-A*02:01 positive uveal melanoma (ID1441)
In development [GID-TA10428] Expected publication date: 04 May 2022
-
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]
Proposed [GID-TA10552] Expected publication date: TBC
-
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]
In development [GID-TA10587] Expected publication date: 02 June 2021
-
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509
In development [GID-TA10413] Expected publication date: TBC
-
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]
Proposed [GID-TA10691] Expected publication date: TBC
-
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Proposed [GID-TA10694] Expected publication date: TBC
-
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]
Proposed [GID-TA10698] Expected publication date: TBC
-
Etranacogene dezaparvovec for treating haemophilia B [ID3812]
Proposed [GID-TA10699] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]
Proposed [GID-TA10702] Expected publication date: TBC
-
Eptinezumab for preventing migraine [ID3803]
Proposed [GID-TA10677] Expected publication date: TBC
-
Gefapixant for treating refractory chronic cough [ID3789]
Proposed [GID-TA10678] Expected publication date: TBC
-
Remimazolam for general anaesthesia [ID3796]
Proposed [GID-TA10679] Expected publication date: TBC
-
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]
Proposed [GID-TA10680] Expected publication date: TBC
-
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Proposed [GID-TA10682] Expected publication date: TBC
-
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]
Proposed [GID-TA10684] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Proposed [GID-TA10683] Expected publication date: TBC
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Proposed [GID-TA10723] Expected publication date: TBC
-
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]
Proposed [GID-TA10725] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Proposed [GID-TA10726] Expected publication date: TBC
-
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Proposed [GID-TA10431] Expected publication date: TBC
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
Proposed [GID-TA10632] Expected publication date: TBC
-
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]
In development [GID-TA10636] Expected publication date: TBC
-
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Proposed [GID-TA10574] Expected publication date: TBC
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published date: 24 May 2019
-
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
In development [GID-TA10254] Expected publication date: TBC
-
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]
In development [GID-TA10399] Expected publication date: TBC
-
Luspatercept for treating beta-thalassaemia ID1554
In development [GID-TA10506] Expected publication date: TBC
-
Kidney transplantation (rejection) - everolimus [ID117]
In development [GID-TAG241] Expected publication date: TBC
-
Selumetinib for treating differentiated thyroid cancer ID1079
In development [GID-TA10207] Expected publication date: TBC
-
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
In development [GID-TA10249] Expected publication date: TBC
-
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
In development [GID-TA10205] Expected publication date: TBC
-
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development [GID-TA10251] Expected publication date: TBC
-
Eltrombopag for untreated severe aplastic anaemia ID1198
In development [GID-TA10284] Expected publication date: TBC
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
In development [GID-TA10311] Expected publication date: TBC
-
Pembrolizumab with epacadostat for untreated malignant melanoma ID1423
In development [GID-TA10330] Expected publication date: TBC
-
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228
In development [GID-TA10203] Expected publication date: TBC
-
Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]
In development [GID-TA10149] Expected publication date: TBC
-
Bevacizumab for untreated malignant pleural mesothelioma (ID1183)
In development [GID-TA10197] Expected publication date: TBC
-
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
In development [GID-TAG321] Expected publication date: TBC
-
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]
In development [GID-TA10168] Expected publication date: TBC
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC